Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - Vero Biotech

Next Previous
X
Search
Drug Profile

Nitric oxide inhalation - Vero Biotech

Alternative Names: GeNOsyl; GENOSYL (nitric oxide) gas; GENOSYL Delivery System; GENOSYL® inhaled nitric oxide ; GENOSYL®DS; inhaled Nitric oxide - VERO Biotech; iNO - VERO Biotech; MVG-2000

Latest Information Update: 07 Feb 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeNO LLC
  • Developer Vero Biotech
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoxic respiratory failure
  • New Molecular Entity No

Highest Development Phases

  • Registered Anaesthesia; Hypoxic respiratory failure
  • Phase II Pulmonary arterial hypertension
  • No development reported Cardiovascular disorders

Most Recent Events

  • 02 Feb 2023 Registered for Anaesthesia in USA (Inhalation)
  • 30 Dec 2022 No development reported - Clinical-Phase-Unknown for Cardiovascular disorders in USA (Inhalation)
  • 15 Dec 2020 US FDA approves use of the GENOSYL Delivery System for nitric oxide inhalation administration during inter-hospital patient transport and in magnetic resonance imaging setting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top